BTIG raised target for Verastem Oncology stock from USD 18.00 to USD 24.00
Published on 10/27/2026 at 14:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical data and valuation
- BTIG lifted its target from USD 18.00 to USD 24.00 on October 15, 2026.
- Verastem reported a 50 percent response rate in second-line pancreatic cancer at the October 7, 2026 data cutoff.
- Verastem Oncology stock trades at EUR 8.96 at 2:12 p.m. CET at Lang & Schwarz on October 27, 2026.
- Third-quarter 2026 results are scheduled for November 5, 2026.
Verastem Oncology (ISIN US92337C2035) was trading at EUR 8.96 at Lang & Schwarz on October 27, 2026, at 2:12 p.m. CET. On October 15, 2026, BTIG raised its target from USD 18.00 to USD 24.00, according to Yahoo Finance.
BTIG target reaches USD 24.00
The target change followed Verastem's October 14 update on VS-7375, an investigational KRAS G12D inhibitor. The company reported a 50 percent confirmed objective response rate in second-line pancreatic cancer at the October 7, 2026 data cutoff, based on four responses among eight patients receiving the 900 mg daily dose, according to the same Yahoo Finance report.
What does the trial mean?
The clinical signal is material because Verastem also aligned with the U.S. Food and Drug Administration on a Phase 3 design for first-line metastatic pancreatic cancer. The company plans to open that study by the end of 2026, while the existing business remains loss making.
For the second quarter of 2026, Verastem reported revenue of USD 40.08 million against a consensus estimate of USD 22.88 million, while adjusted earnings per share were negative USD 0.35 versus a negative USD 0.43 estimate, as reported by MarketBeat on October 22, 2026.
Three milestones since October 7
On October 7, 2026, the Food and Drug Administration accepted Verastem's priority-review application for the first quarter of 2027. On October 12, 2026, the company estimated third-quarter net product revenue at USD 23.9 million to USD 24.1 million, compared with USD 11.2 million a year earlier, in an SEC filing. On October 15, 2026, BTIG lifted its target to USD 24.00 from USD 18.00.
Upcoming dates
Verastem's investor-relations page lists third-quarter 2026 results for November 5, 2026, followed by an earnings call at 4:30 p.m. EST. Michael P. Bailey is scheduled to become chief executive officer on January 1, 2027, according to the company's October 12 filing.
Euro quote and valuation
The primary listing is on the Nasdaq Capital Market, while the current German-market indication places the company at USD 905.6 million in market value as of October 27, 2026. Its 52-week primary-market range is USD 3.43 to USD 10.82 as of October 26, 2026.
Verastem Oncology was trading at EUR 8.96 at Lang & Schwarz on October 27, 2026, at 2:12 p.m. CET.
The further course of trading is shown by the continuously updated real-time quote of Verastem Oncology stock.
Verastem Oncology stock facts
- Company: Verastem, Inc.
- ISIN: US92337C2035
- Ticker: VSTM
- Primary exchange: Nasdaq Capital Market
- Price Lang & Schwarz (as of October 27, 2026, 2:12 p.m. CET): EUR 8.96
- Market capitalization: USD 905.6 million (as of October 27, 2026)
- 52-week range: USD 3.43-10.82 (as of October 26, 2026)
- Sector / Industry: Biotechnology / Medical Research
- Next earnings date: November 5, 2026
Market context: Market report S&P 500.
